GlassScriptPhysician profile
Lawrence Letellier
NPI 1245834597
$2,322.05
in general payments reported to CMS, 2019-2025
17 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $364 · 2022: $408 · 2023: $699 · 2024: $563 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $890.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $303.43 | 2022-2023 | |
| Amgen INC. | $253.04 | 2023-2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $197.86 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $157.89 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.42 | 2024 | |
| Si-Bone, INC. | $68.32 | 2021-2022 | |
| Medtronic, INC. | $65.49 | 2023-2025 | Vanta Adaptivestim, Intellis Adaptivestim |
| Exact Sciences Corporation | $64.77 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $57.88 | 2024-2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $56.65 | 2023-2024 | Nuedexta |
| Lilly USA, LLC | $38.64 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Nevro Corp. | $28.45 | 2024 | Senza |
| Alk-Abello, INC | $23.05 | 2023 | Ragwitek, Grastek, Odactra |
| Acerus Pharmaceuticals Corporation | $19.41 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Letellier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.